

Meeting Faculty

Karen E. Hansen, MD, MS

Dr. Karen Hansen is an associate professor in the Divisions of Rheumatology and Endocrinology at the University of Wisconsin School of Medicine & Public Health. Most of her time is spent as a clinical researcher focusing on multiple aspects of osteoporosis. She has completed clinical trials investigating changes in fractional intestinal calcium absorption with treatment of vitamin D insufficiency, use of proton pump inhibitors and use of aromatase inhibitors in women with early stage breast cancer.

Dr. Hansen completed a single center, randomized double-blind placebo-controlled trial to evaluate the effects of low and high dose vitamin D on calcium absorption, bone mineral density and muscle fitness in postmenopausal women with vitamin D insufficiency. Work in glucocorticoid induced osteoporosis included co-authorship of the recent American College of Rheumatology guidelines, and a systematic review and meta-analysis on the effects of glucocorticoid therapy in children. Dr. Hansen will focus her talk on care gaps in osteoporosis, opportunities to close those care gaps, and new medications recently developed to treat osteoporosis.



John D. Reveille, MD

Dr. Reveille received his rheumatology training at John Hopkins University in the 1980s. After his fellowship, he became assistant professor at the University of Alabama for four years before joining the faculty of UT Physicians in 1987 where he was associate professor for three years and later became professor.

In 1997, Dr. Reveille received the Alfred and Anna Bohn Memorial Award for Service to the Lupus Foundation of America. He also received the Outstanding Achievement Award from the Spondylitis Association of America in 2003 and served on their Medical Advisory Board (1987-present, Chairman 1993-95, 2015-18) and on the SAA Board of Directors 2007-2014.

Dr. Reveille was president of the Pan American League of Associations of Rheumatology (PANLAR) 2012-2014 and was a standing member of the Arthritis, Connective Tissue and Skin Diseases (ACTS) NIH Study Section 2007-2011 and was Chairman from 2008-2010.

Dr. Reveille is involved in Phase III studies of biologic therapies for ankylosing spondylitis and has been named one of the Best Doctors in America every year since 2008.



Michael Wechsler, MD

Dr. Wechsler is director of the National Jewish Health (NJH)/Cohen Family Asthma Institute and professor of medicine in the Division of Pulmonary, Critical Care, and Sleep Medicine at NJH in Denver, Colorado. His research focuses on clinical and translational asthma with an emphasis on clinical trials in asthma, novel asthma therapies, bronchial thermoplasty, asthma pharmacogenomics, and management of eosinophilic granulomatosis with polyangiitis (i.e. Churg-Strauss Syndrome [CSS]). He has led several studies focusing on novel biologic agents for asthma and related diseases and has published more than 180 peer-reviewed manuscripts relating to asthma, CSS and eosinophilic lung diseases.



Dr. Wechsler was a member of the Steering Committee and site Principal Investigator (PI) for the NIH-sponsored Asthma Clinical Research Network (ACRN, now called AsthmaNet), a multi-center asthma clinical-trials consortium. He serves as the PI of the Denver site of the Precision Intervention in Severe/Exacerbating Asthma (PRECISE) network. A member of the American Society of Clinical Investigation, Dr. Wechsler has participated in many different task forces related to the study of eosinophilic lung diseases that were sponsored by the NIH, the FDA, the European Respiratory Society, and the International Eosinophil Society. He is currently associate editor of the journal *Chest* and has served as associate editor of *Allergy* and on the editorial board of the *European Journal of Clinical Investigation*.

Dr. Wechsler received AB and MMSc degrees from Harvard University in Boston and his medical doctorate from McGill University in Montreal. He completed medical training at Beth Israel Hospital in Boston, and as part of the Harvard Combined Pulmonary and Critical Care Fellowship Training Program.